Literature DB >> 25009229

Cortical GABAergic excitation contributes to epileptic activities around human glioma.

Michel Le Van Quyen1, Franck Bielle2, Christophe Pellegrino3,4, Johan Pallud1,5,6, Pascale Varlet7, Noemie Cresto1, Michel Baulac1,8, Charles Duyckaerts2, Nazim Kourdougli3,4, Geneviève Chazal3,4, Bertrand Devaux5,6, Claudio Rivera3,4,9, Richard Miles1, Laurent Capelle1,10, Gilles Huberfeld1,2,8,11.   

Abstract

Brain gliomas are highly epileptogenic. Excitatory glutamatergic mechanisms are involved in the generation of epileptic activities in the neocortex surrounding gliomas. However, chloride homeostasis is known to be perturbed in glioma cells. Thus, the contribution of γ-aminobutyric acidergic (GABAergic) mechanisms that depend on intracellular chloride merits closer study. We studied the occurrence, networks, cells, and signaling basis of epileptic activities in neocortical slices from the peritumoral surgical margin resected around human brain gliomas. Postoperative glioma tissue from 69% of patients spontaneously generated interictal-like discharges, synchronized, with a high-frequency oscillation signature, in superficial layers of neocortex around areas of glioma infiltration. Interictal-like events depended both on glutamatergic AMPA receptor-mediated transmission and on depolarizing GABAergic signaling. GABA released by interneurons depolarized 65% of pyramidal cells, in which chloride homeostasis was perturbed because of changes in expression of neuronal chloride cotransporters: KCC2 (K-Cl cotransporter 2) was reduced by 42% and expression of NKCC1 (Na-K-2Cl cotransporter 1) increased by 144%. Ictal-like activities were initiated by convulsant stimuli exclusively in these epileptogenic areas. This study shows that epileptic activities are sustained by excitatory effects of GABA in human peritumoral neocortex, as reported in temporal lobe epilepsies, suggesting that both glutamate and GABA signaling and cellular chloride regulation processes, all also involved in oncogenesis as already shown, induce an imbalance between synaptic excitation and inhibition underlying epileptic discharges in glioma patients. Thus, the control of chloride in neurons and glioma cells may provide a therapeutic target for patients with epileptogenic gliomas.
Copyright © 2014, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25009229      PMCID: PMC4409113          DOI: 10.1126/scitranslmed.3008065

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  56 in total

1.  Anomalous levels of Cl- transporters cause a decrease of GABAergic inhibition in human peritumoral epileptic cortex.

Authors:  Luca Conti; Eleonora Palma; Cristina Roseti; Clotilde Lauro; Raffaela Cipriani; Marjolein de Groot; Eleonora Aronica; Cristina Limatola
Journal:  Epilepsia       Date:  2011-06-02       Impact factor: 5.864

2.  [Electrocorticogram and unitary activites with expanding lesions in man].

Authors:  J F Hirsch; J Buisson-Ferey; M Sachs; J C Hirsch; J Scherrer
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1966-11

3.  Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas.

Authors:  Jonathan H Sherman; Krisztina Moldovan; H Kwang Yeoh; Robert M Starke; Nader Pouratian; Mark E Shaffrey; David Schiff
Journal:  J Neurosurg       Date:  2011-01-14       Impact factor: 5.115

Review 4.  Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management.

Authors:  Melanie S M van Breemen; Erik B Wilms; Charles J Vecht
Journal:  Lancet Neurol       Date:  2007-05       Impact factor: 44.182

5.  NKCC1 transporter facilitates seizures in the developing brain.

Authors:  Volodymyr I Dzhala; Delia M Talos; Dan A Sdrulla; Audrey C Brumback; Gregory C Mathews; Timothy A Benke; Eric Delpire; Frances E Jensen; Kevin J Staley
Journal:  Nat Med       Date:  2005-10-09       Impact factor: 53.440

6.  Epilepsy in cerebral glioma: timing of appearance and histological correlations.

Authors:  Anna Rosati; Alessia Tomassini; Bianca Pollo; Claudia Ambrosi; Andreas Schwarz; Alessandro Padovani; Bruno Bonetti
Journal:  J Neurooncol       Date:  2009-01-29       Impact factor: 4.130

7.  Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response.

Authors:  A Pace; A Vidiri; E Galiè; M Carosi; S Telera; A M Cianciulli; P Canalini; D Giannarelli; B Jandolo; C M Carapella
Journal:  Ann Oncol       Date:  2003-12       Impact factor: 32.976

8.  Low-grade gliomas associated with intractable epilepsy: seizure outcome utilizing electrocorticography during tumor resection.

Authors:  M S Berger; S Ghatan; M M Haglund; J Dobbins; G A Ojemann
Journal:  J Neurosurg       Date:  1993-07       Impact factor: 5.115

9.  Amino acids in the neuronal microenvironment of focal human epileptic lesions.

Authors:  A Hamberger; B Nyström; S Larsson; H Silfvenius; C Nordborg
Journal:  Epilepsy Res       Date:  1991 May-Jun       Impact factor: 3.045

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  75 in total

1.  Risk factors for intraoperative stimulation-related seizures during awake surgery: an analysis of 109 consecutive patients.

Authors:  Giannantonio Spena; Elena Roca; Francesco Guerrini; Pier Paolo Panciani; Lorenzo Stanzani; Andrea Salmaggi; Sabino Luzzi; Marco Fontanella
Journal:  J Neurooncol       Date:  2019-09-24       Impact factor: 4.130

2.  High expression of cystine-glutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma.

Authors:  Mai Froberg Sørensen; Sólborg Berglind Heimisdóttir; Mia Dahl Sørensen; Casper Schau Mellegaard; Helle Wohlleben; Bjarne Winther Kristensen; Christoph Patrick Beier
Journal:  J Neurooncol       Date:  2018-02-05       Impact factor: 4.130

3.  Compromising KCC2 transporter activity enhances the development of continuous seizure activity.

Authors:  Matthew R Kelley; Tarek Z Deeb; Nicholas J Brandon; John Dunlop; Paul A Davies; Stephen J Moss
Journal:  Neuropharmacology       Date:  2016-04-21       Impact factor: 5.250

Review 4.  Hippocampal sharp wave-ripple: A cognitive biomarker for episodic memory and planning.

Authors:  György Buzsáki
Journal:  Hippocampus       Date:  2015-10       Impact factor: 3.899

5.  AMPAR-mediated Interictal Discharges in Neurons of Entorhinal Cortex: Experiment and Model.

Authors:  A V Chizhov; D V Amakhin; A V Zaizev; L G Magazanik
Journal:  Dokl Biol Sci       Date:  2018-05-22

6.  Do not omit the grade of malignancy when correlating the lobar location of diffuse gliomas and the risk of preoperative epileptic seizures.

Authors:  Johan Pallud; Marc Zanello; Alexandre Roux
Journal:  Neurosurg Rev       Date:  2018-10-11       Impact factor: 3.042

7.  Mannitol decreases neocortical epileptiform activity during early brain development via cotransport of chloride and water.

Authors:  J Glykys; E Duquette; N Rahmati; K Duquette; K J Staley
Journal:  Neurobiol Dis       Date:  2019-02-01       Impact factor: 5.996

Review 8.  Seizures in oligodendroglial tumors.

Authors:  Melissa Kerkhof; Christa Benit; Alberto Duran-Pena; Charles J Vecht
Journal:  CNS Oncol       Date:  2015-10-19

9.  Hyperexcitability of the network contributes to synchronization processes in the human epileptic neocortex.

Authors:  Kinga Tóth; Katharina T Hofer; Ágnes Kandrács; László Entz; Attila Bagó; Loránd Erőss; Zsófia Jordán; Gábor Nagy; András Sólyom; Dániel Fabó; István Ulbert; Lucia Wittner
Journal:  J Physiol       Date:  2017-12-28       Impact factor: 5.182

10.  Acute and chronic efficacy of bumetanide in an in vitro model of posttraumatic epileptogenesis.

Authors:  Volodymyr Dzhala; Kevin J Staley
Journal:  CNS Neurosci Ther       Date:  2014-12-12       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.